283 results about "Retinal" patented technology

The invention belongs to the technical field of biological medicine, and discloses an application of CDH5 protein and / or SELL protein as a biomarker in preparation of a kit for detecting diabetic retinopathy, the biomarker comprises at least one of CDH5 protein and SELL protein; the amino acid sequence of the CDH5 protein is as shown in SEQ NO: 1, and the amino acid sequence of the SELL protein is as shown in SEQ NO: 2. The CDH5 protein and / or the SELL protein are / is used as the biomarker for detecting diabetic retinopathy, especially for detecting early diabetic retinopathy, good sensitivity and specificity can be obtained, the accuracy of a detection result is ensured, early diagnosis and early treatment are realized, sampling is convenient and non-invasive, and large-scale popularization can be realized.

The invention provides a composition which comprises two components, and the component A comprises lutein; and the component B comprises a berry fruit extract containing anthocyanin. The composition has the effects of eliminating free radicals, resisting oxidation, protecting eyes, inhibiting tear secretion reduction, relieving eyestrain and eye dryness, relieving ciliary muscle tension, repairing retina, preventing and controlling ocular axes, protecting eyesight, preventing myopia, improving eye microcirculation, improving couperose skin and the like.

The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

The invention belongs to the technical field of marine microorganisms, and discloses an application of Propionibacterium fredenreici subsp. Schermani NHNK-616 in preparation of a product for improving macular retinae, the Propionibacterium fredenreici subsp. Schermani NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the Propionibacterium fredenreici subsp. Schermani NHNK-616 is CCTCC NO: M 20241429. The invention further discloses a preparation method of the Propionibacterium fredenreici subsp. Schermani NHNK-616. The inventor finds that the NHNK-616 has the functions of improving the oxidation resistance of the retina, increasing the retinal barrier, reducing retinal neovascularization, reducing retinal inflammation and the like, in addition, an NHNK-616 thallus biological membrane can improve the colonization capacity of nasal epithelial cells and intestinal epithelial cells, and the NHNK-616 can be used for preparing products for improving the retina macular.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

A trace element supplement consisting of lutein, zeaxanthin, astaxanthin, anthocyanins, and proanthocyanidins is designed to improve retinal health in children and adolescents, relieve eye strain, and slow the progression of myopia. The daily dose is 1–20 mg lutein, 0.2–4 mg zeaxanthin, 0.5–8 mg astaxanthin, 10–700 mg taurine, and 0.5–8.5 mg zinc; the nighttime dose is 1–100 mg eyebright extract, 10–300 mg chamomile extract, 1–200 mg anthocyanins, and 1–500 mg proanthocyanidins.

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

The present invention discloses a method for culturing vitreoretinal organoids in vitro, comprising the following steps: (1) amplifying and culturing pluripotent stem cells to a cell confluence of 50% to 90%; (2) on day 0, digesting the stem cells with a digestion solution; adding a neurosphere culture medium for culturing; adding matrigel for culturing, and then adding a neurosphere culture medium for culturing to obtain a cell suspension; (3) adding a ROCK pathway inhibitor to the cell suspension, and culturing in the neurosphere culture medium for 3 to 5 days to obtain ectoderm neurospheres; (4) replacing the neurosphere culture medium with a vitreous culture medium I, adding TGFB1 protein, and placing the cell suspension on a shaker for 25 to 28 days; (5) replacing the vitreous culture medium I with a vitreous culture medium II, and culturing the cell suspension for 60 to 300 days to obtain vitreoretinal organoids. The vitreous organoids of the retina cultured in vitro according to the present invention can simulate the vitreous in vivo.

The invention relates to a supramolecular nano gene vector as well as a preparation method and application thereof. The supramolecular nano-carrier is prepared from beta-cyclodextrin grafted polyethyleneimine, 8-adamantane grafted polyamide-amine dendrimer, adamantane grafted polyethylene glycol and adamantane grafted polyethylene glycol modified by using a cell penetrating peptide (TAT). A CRISPR / Cas9 system is loaded through self-assembly of a nano material monomer, the prescription is screened, and the subsequent research on cells and retinal organs proves that the transfection efficiency and the RS1 protein expression quantity are good. The supramolecular nanoparticle loaded gene editing system has a good potential of treating the X-linked retina cleavage disease. Moreover, the supramolecular nanoparticle gene vector is high in biological safety, high in transfection efficiency, simple and easily available in preparation mode, and good in clinical application potential in the future.

The invention relates to gene therapy of ocular conditions. Described herein are compositions and methods for delivering therapeutic products, such as therapeutic proteins (e.g., antibodies), therapeutic RNAs (e.g., shRNAs, siRNAs, and miRNAs), and therapeutic aptamers, to the retinal / vitreous humor of the eye of a human subject to treat ocular conditions, involving, for example, recombinant viral vectors, such as recombinant adeno-associated virus (rAAV) vectors.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

A mixer attachment for use with a surgical hand piece includes a powder plate configured to contain a solid substance for combining with a liquid substance to form a combined substance. The mixer attachment further includes a plurality of mixing plates configured to mix the solid substance and the liquid substance in the combined substance, the plurality of mixing plates including: one or more channeled plates comprising one or more channels and one or more through holes configured to facilitate turbulent flow of the combined substance during mixing, and one or more flat plates comprising a central opening to direct flow of the combined substance between the one or more channeled plates.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present invention discloses a β-carotene-grape seed extract eye-care preparation for retinal protection, relating to functional health foods. The preparation comprises active components and food-acceptable excipients. In parts by weight, the active components include 1–4 parts lutein, 0.5 –2 parts meso-zeaxanthin, 2 – 6 parts β-carotene, 8 – 25 parts blueberry extract, 5 – 18 parts grape seed extract, 0.2–1 part L-ergothioneine, 0.5–3 parts saffron extract, and 1–5 parts phosphatidylserine. The excipients comprise a filler, disintegrant, binder, and lubricant, with a weight ratio of active components to excipients of 1:1 to 1:4. By combining these eight components at specific ratios, the invention achieves synergistic effects, protects retinal health, and reduces blue-light damage. Dual-phase microencapsulation based on solubility, together with standardized preparation steps, improves stability and utilization efficiency.

The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an αv integrin, such as diabetic retinopathy.

The invention discloses a vitrification protective agent for retina organoid and application of the vitrification protective agent, and belongs to the technical field of organoid cryopreservation. The vitrification protective agent provided by the invention consists of 22wt% of dimethyl sulfoxide, 8wt% of ethylene glycol, 0.5 M sucrose and the balance of a culture medium. The invention also provides an application of the vitrification protective agent in retina organ cryopreservation. According to the invention, by improving the components of the protective agent, optimizing the loading and removing mode of the protective agent and selecting the cryopreservation carrier, the high-quality preservation of the retinal organs is realized. Compared with the prior art, the method has the advantages that the vitrification concentration is low, the retina organoid is fast to recover, the structural function is completely preserved, freezing and resuscitation of the retina organoid can be efficiently achieved in a high-throughput and simple-operation mode, and application requirements can be met.

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

The utility model provides a retina injector. The retina injector comprises a liquid injection body, an injection needle, a piston and an administration dosage control structure. The liquid injection body is provided with a hollow cavity used for containing liquid, a liquid injection opening and a material pushing opening, the liquid injection opening is communicated with the cavity and used for injecting the liquid into the cavity, and the material pushing opening is formed in one end of the cavity and communicated with the cavity. The injection needle is connected to one end of the liquid injection body. The piston is arranged in the cavity in a sliding mode through the material pushing opening. The administration dosage control structure is arranged in a mounting groove in the liquid injection body and is sealed with the mounting groove. The administration dosage control structure comprises a fixing assembly, a cover plate, a first material blocking part and a second material blocking part, the first material blocking part and the second material blocking part are both connected to the cover plate, the cover plate is movably connected to the fixing assembly, and the first material blocking part and the second material blocking part are of a linkage structure which ascends and descends in the cavity. The cover plate is operated so that the first material blocking piece or the second material blocking piece can movably stretch into the cavity to prevent the piston from sliding forwards.

The invention provides a blueberry fruit extract composition containing anthocyanin. The composition has the effects of eliminating free radicals, resisting oxidation, protecting eyes, inhibiting tear secretion reduction, relieving eyestrain and eye dryness, repairing retina, protecting eyesight, preventing and controlling myopia, improving eye blood circulation and the like.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

This invention relates to the field of traditional Chinese medicine (TCM) technology. The invention provides a TCM composition for treating glaucoma and its preparation method, comprising the following components in parts by weight: 18-28 parts of Cassia seed, 12-18 parts of Lycium fruit, 12-18 parts of Eriocaulon buergerianum, 10-15 parts of vinegar-processed Cyperus rotundus, 10-15 parts of mulberry leaf, 10-15 parts of Ligusticum chuanxiong, 8-12 parts of Polyporus umbellatus, 5-8 parts of Pueraria lobata, 5-8 parts of Akebia quinata, 3-5 parts of Curcuma longa, 3-5 parts of Indigo naturalis, and 2-4 parts of prepared licorice root. The TCM composition of this invention has a strong effect in lowering intraocular pressure, improving retinal blood supply, and preventing optic nerve atrophy caused by glaucoma; simultaneously, the processing method maximizes the retention of the active pharmaceutical ingredients. Furthermore, the technical solution of this invention achieves a dual improvement in efficacy and safety, and also reduces the recurrence rate and side effects.

The present invention provides methods for treating or preventing diabetic retinopathy. e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include administering 2 mg of aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and an 8-week interval (2q16). In addition. the present invention provides methods for reversing or halting the progression of NPDR to PDR (e.g., such that NPDR is reduced by 2 or 3 levels) or preventing the occurrence or recurrence of a vision-threatening complication by administering aflibercept according to the dosage regimens presented herein.

The application discloses a preparation method and application of a paeonol derivative, and relates to the technical field of biomedicine. The paeonol derivative has the chemical structure as shown in the following formula: or. The paeonol extraction preparation method is simple, and the extraction rate of the paeonol is high. The prepared paeonol derivative has more excellent antioxidant activity, and the anti-inflammatory effect is enhanced, the anti-platelet aggregation effect is better, and the paeonol derivative also has good inhibitory activity on the occurrence and development of diabetic retinopathy.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

Provided are sequence variants and fusion proteins of the photosensitive ion channel protein ChRmine and their use in treating retinal neurodegenerative diseases. These ChRmine variants and fusion proteins exhibit improved protein properties and enhanced photoresponsive characteristics compared with the wildtype ChRmine, therefore may provide effective optogenetic tools to improve the therapeutic treatment of the retinal neurodegenerative diseases.